InvestorsHub Logo
Followers 33
Posts 1924
Boards Moderated 1
Alias Born 08/02/2019

Re: sunspotter post# 397063

Sunday, 03/26/2023 2:25:44 PM

Sunday, March 26, 2023 2:25:44 PM

Post# of 403122
Here is the claim. Brilacidin is:

a drug which causes the majority of those receiving it to experience either hypertensive crises or peripheral neuropathy, or very often both.


Hypertensive crises? Certainly with such a dangerous and scary crisis like this I am sure many who received Brilacidin would have to stop the test. But how many did? Look at your data.

Peripheral neuropathy? This also sounds super scary and serious.
"Nerve damage that causes pain, tingling, numbness, or weakness in the extremities is known as peripheral neuropathy, and it can cause impairment in sensation or both sensation and strength. It may affect a person’s ability to walk or participate fully in their everyday activities, which may negatively impact their quality of life."
https://www.yalemedicine.org/conditions/peripheral-neuropathy
Certainly persons in the ABSSSI test who had serious nerve damage from Brilacidin would have to stop the test. How many did? Look at your data.

Brilacidin did cause temporary numbness and tingling in some persons. Lidocaine also causes temporary numbness. Is it toxic? Should Lidocaine be considered dangerous and never used again?

Do you need a list of drugs that cause temporary tingling?
https://www.medindia.net/drugs/side-effects/paresthesia.htm

I would like entered in the record that the USA FDA has said it is okay to give Brilacidin to persons in the mouth and in the rectum and direct in the blood in other clinical trials. If Brilacidin was not safe in their opinion they would not allow this. I trust the USA FDA one million times more than anonymous persons in social media. The claim that Brilacidin is dangerous is false even it it appears almost every day. Repeating a lie does not make it truth.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News